News

18 Nov: LSO Submission to the HESA study on PMPRB

Subject: HESA study on the reforms of the Patented Medicine Prices Review Board (PMPRB) Dear Honourable Members,Life Sciences Ontario (LSO) is a not-for-profit organization that represents and promotes Ontario’s vibrant and diverse life sciences sector. Members of LSO include life sciences companies, entrepreneurs, members of academia, and service providers from…

13 Aug: LSO RESPONDS TO THE PMPRB’S JUNE 2020 DRAFT GUIDELINES CONSULTATION

Life Sciences Ontario remains deeply concerned about the federal government’s patented medicine price controls and their potential to undermine the life sciences sector’s efforts to support the health and well-being of Canadians and the economy, particularly during the unprecedented COVID-19 pandemic. There is a growing body of evidence showing that…

02 Jun: LSO supports delay of federal drug pricing rules implementation

Life Sciences Ontario applauds the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations to January 1, 2021 as part of the response to the COVID-19 crisis. This measure will help the Canadian life sciences sector remain unwaveringly focused on developing vaccines, treatments, and other tools to fight…

19 Mar: How LSO Members are combating the spread of COVID-19

LSO put out a call to our members requesting insights on how companies are working together to combat the rapid spread of the novel COVID-19 virus. Below are some examples of how we, as a community are helping to control the outbreak. Member Announcements Amgen Canada: Amgen will provide its…

03 Feb: New federal drug pricing rules are already delaying medicine launches and costing jobs in Canada, survey reveals

To help measure the impacts of the federal government’s new price controls for patented medicines in Canada, Life Sciences Ontario commissioned Research Etc., an established Toronto research firm, to conduct an anonymous survey of pharmaceutical and other life sciences leaders. The survey, which drew on data from 46 respondents including leaders…

10 Jan: MEMBER ANNOUNCEMENT: adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

Vancouver, Canada – January 9, 2020: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), announced today they are bringing their respective capabilities and resources together under adMare to…